{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:28:42Z","timestamp":1790065722443,"version":"4.0.1"},"reference-count":151,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Duchenne muscular dystrophy (DMD) is an X-linked hereditary disease characterized by progressive muscle wasting due to modifications in the <jats:italic>DMD<\/jats:italic> gene (exon deletions, nonsense mutations, intra-exonic insertions or deletions, exon duplications, splice site defects, and deep intronic mutations) that result in a lack of functional dystrophin expression. Many therapeutic approaches have so far been attempted to induce dystrophin expression and improve the patient phenotype. In this manuscript, we describe the relevant updates for some therapeutic strategies for DMD aiming to restore dystrophin expression. We also present and analyze <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> ongoing experimental approaches to treat the disease.<\/jats:p>","DOI":"10.3389\/fmed.2022.859930","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T23:07:22Z","timestamp":1648595242000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["Therapeutic Strategies for Dystrophin Replacement in Duchenne Muscular Dystrophy"],"prefix":"10.3389","volume":"9","author":[{"given":"Cedric","family":"Happi Mbakam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Lamothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques P.","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1152\/physrev.00028.2001","article-title":"Function and genetics of dystrophin and dystrophin-related proteins in muscle.","volume":"82","author":"Blake","year":"2002","journal-title":"Physiol Rev."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay6812","article-title":"Enhanced CRISPR-Cas9 correction of duchenne muscular dystrophy in mice by a self-complementary AAV delivery system.","volume":"6","author":"Zhang","year":"2020","journal-title":"Sci Adv."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/cphy.c140048","article-title":"The dystrophin complex: structure, function and implications for therapy.","volume":"5","author":"Gao","year":"2015","journal-title":"Compr Physiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.bpj.2018.05.039","article-title":"Dynamics of dystrophin\u2019s actin-binding domain.","volume":"115","author":"Fealey","year":"2018","journal-title":"Biophys J."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsb.2019.107411","article-title":"How the central domain of dystrophin acts to bridge F-actin to sarcolemmal lipids.","volume":"209","author":"Mias-Lucquin","year":"2020","journal-title":"J Struct Biol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1172\/JCI115909","article-title":"An intact cysteine-rich domain is required for dystrophin function.","volume":"90","author":"Bies","year":"1992","journal-title":"J Clin Invest."},{"key":"B7","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/sj.embor.7400221","article-title":"Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment.","volume":"5","author":"Nowak","year":"2004","journal-title":"EMBO Rep."},{"key":"B8","year":"2006","journal-title":"Dystrophin Isoforms and Their Expression [Internet]."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01430-8","article-title":"Global epidemiology of duchenne muscular dystrophy: an updated systematic review and meta-analysis.","volume":"15","author":"Crisafulli","year":"2020","journal-title":"Orphanet J Rare Dis."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0631-3","article-title":"The burden, epidemiology, costs and treatment for duchenne muscular dystrophy: an evidence review.","volume":"12","author":"Ryder","year":"2017","journal-title":"Orphanet J Rare Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD global database: analysis of more than 7,000 duchenne muscular dystrophy mutations.","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum Mutat."},{"key":"B12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/BF00283688","article-title":"Molecular deletion patterns in duchenne and becker type muscular dystrophy.","volume":"81","author":"Liechti-Gallati","year":"1989","journal-title":"Hum Genet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3233\/PRM-160361","article-title":"Age at onset of first signs or symptoms predicts age at loss of ambulation in duchenne and becker muscular dystrophy: data from the MD STARnet.","volume":"9","author":"Ciafaloni","year":"2016","journal-title":"J Pediatr Rehabil Med."},{"key":"B14","year":"2020","journal-title":"Duchenne Muscular Dystrophy | Genetic and Rare Diseases Information Center (GARD) \u2013 an NCATS Program [Internet]."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00970","article-title":"HLA polymorphism affects risk of de novo mutation of dystrophin gene and clinical severity of duchenne muscular dystrophy in a Southern Chinese population.","volume":"9","author":"Li","year":"2018","journal-title":"Front Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jocn.2006.12.012","article-title":"Follow-up of three patients with a large in-frame deletion of exons 45\u201355 in the duchenne muscular dystrophy (DMD) gene.","volume":"15","author":"Nakamura","year":"2008","journal-title":"J Clin Neurosci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/343180a0","article-title":"Very mild muscular dystrophy associated with the deletion of 46% of dystrophin.","volume":"343","author":"England","year":"1990","journal-title":"Nature."},{"key":"B18","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/ana.22024","article-title":"Gentamicin-induced readthrough of stop codons in duchenne muscular dystrophy.","volume":"67","author":"Malik","year":"2010","journal-title":"Ann Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1172\/JCI8055","article-title":"Correction of genetic disease by making sense from nonsense.","volume":"104","author":"Kaufman","year":"1999","journal-title":"J Clin Invest."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/genes11080837","article-title":"Therapeutic strategies for duchenne muscular dystrophy: an update.","volume":"11","author":"Sun","year":"2020","journal-title":"Genes (Basel)."},{"key":"B21","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1172\/JCI7866","article-title":"Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice.","volume":"104","author":"Barton-Davis","year":"1999","journal-title":"J Clin Invest."},{"key":"B22","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ana.1023","article-title":"Gentamicin treatment of duchenne and becker muscular dystrophy due to nonsense mutations.","volume":"49","author":"Wagner","year":"2001","journal-title":"Ann Neurol."},{"key":"B23","first-page":"15","article-title":"Gentamicin administration in duchenne patients with premature stop codon. preliminary results.","volume":"22","author":"Politano","year":"2003","journal-title":"Acta Myol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/bcp.13439","article-title":"Adverse effects of a single dose of gentamicin in adults: a systematic review.","volume":"84","author":"Hayward","year":"2018","journal-title":"Br J Clin Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-018-0024-7","article-title":"Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons.","volume":"24","author":"Dabrowski","year":"2018","journal-title":"Mol Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/nbt0814-706","article-title":"EMA reconsiders \u2018read-through\u2019 drug against duchenne muscular dystrophy following appeal.","volume":"32","author":"Mullard","year":"2014","journal-title":"Nat Biotechnol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet."},{"key":"B28","year":"2021","journal-title":"PTC Therapeutics: Hosts Call to Review Results of TranslarnaTM (ataluren) | Duchenne Muscular Dystrophy | Jesse\u2019s Journey | Canada [Internet]. Duchenne Muscular Dystrophy | Jesse\u2019s Journey."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22040563","article-title":"Antisense oligonucleotide-based therapy for neuromuscular disease.","volume":"22","author":"Sardone","year":"2017","journal-title":"Molecules."},{"key":"B30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1146\/annurev-neuro-070918-050501","article-title":"Antisense oligonucleotide therapies for neurodegenerative diseases.","volume":"42","author":"Bennett","year":"2019","journal-title":"Annu Rev Neurosci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform.","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nrg3460","article-title":"Therapy for duchenne muscular dystrophy: renewed optimism from genetic approaches.","volume":"14","author":"Fairclough","year":"2013","journal-title":"Nat Rev Genet."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1113\/EP085308","article-title":"Advances in genetic therapeutic strategies for duchenne muscular dystrophy.","volume":"100","author":"Guiraud","year":"2015","journal-title":"Exp Physiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/nat.2016.0657","article-title":"Approves eteplirsen for duchenne muscular dystrophy: the next chapter in the eteplirsen saga.","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1002\/acn3.51235","article-title":"Viltolarsen in Japanese duchenne muscular dystrophy patients: a phase 1\/2 study.","volume":"7","author":"Komaki","year":"2020","journal-title":"Ann Clin Transl Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with duchenne muscular dystrophy.","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology."},{"key":"B37","year":"2020","journal-title":"FDA Grants Accelerated Approval to First Drug for Duchenne Muscular Dystrophy [Internet]."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218683","article-title":"Long-term natural history data in duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53.","volume":"14","author":"Brogna","year":"2019","journal-title":"PLoS One."},{"key":"B39","year":"2021","journal-title":"Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 | Sarepta Therapeutics, Inc. [Internet]."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of viltolarsen in boys with duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial.","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol."},{"key":"B41","year":"2021","journal-title":"Sarepta Therapeutics Announces FDA Approval of AMONDYS 45TM (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45 | Sarepta Therapeutics, Inc. [Internet]."},{"key":"B42","year":"2021","journal-title":"Amondys 45 (Casimersen) - Muscular Dystrophy News [Internet]."},{"key":"B43","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nsmb1075","article-title":"In vivo assembly of functional U7 snRNP requires RNA backbone flexibility within the Sm-binding site.","volume":"13","author":"Kolev","year":"2006","journal-title":"Nat Struct Mol Biol."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a003707","article-title":"Spliceosome structure and function.","volume":"3","author":"Will","year":"2011","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1038\/mt.2012.178","article-title":"Exon 45 skipping through U1-snRNA antisense molecules recovers the Dys-nNOS pathway and muscle differentiation in human DMD myoblasts.","volume":"20","author":"Cazzella","year":"2012","journal-title":"Mol Ther."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1126\/science.1104297","article-title":"Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.","volume":"306","author":"Goyenvalle","year":"2004","journal-title":"Science."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/mt.2012.26","article-title":"Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for duchenne muscular dystrophy.","volume":"20","author":"Goyenvalle","year":"2012","journal-title":"Mol Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.nmd.2015.08.005","article-title":"The first exon duplication mouse model of duchenne muscular dystrophy: a tool for therapeutic development.","volume":"25","author":"Vulin","year":"2015","journal-title":"Neuromuscul Disord."},{"key":"B49","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.omtm.2021.03.014","article-title":"Pre-clinical dose-escalation studies establish a therapeutic range for U7snRNA-mediated DMD exon 2 skipping.","volume":"21","author":"Simmons","year":"2021","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B50","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1089\/hum.2020.286","article-title":"Lack of toxicity in nonhuman primates receiving clinically relevant doses of an AAV9.U7snRNA vector designed to induce DMD exon 2 skipping.","volume":"32","author":"Gushchina","year":"2021","journal-title":"Hum Gene Ther."},{"key":"B51","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2019.06.196","article-title":"140RNA-Seq shows an absence of off-target splicing effects in AAV9-U7snRNA mediated skipping of DMD exon 2.","volume":"29","author":"Flanigan","year":"2019","journal-title":"Neuromuscul Disord."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1089\/hum.2020.315","article-title":"Absence of significant off-target splicing variation with a U7snRNA vector targeting DMD exon 2 duplications.","volume":"32","author":"Wein","year":"2021","journal-title":"Hum Gene Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3892\/ijmm.2019.4112","article-title":"Genome editing: a perspective on the application of CRISPR\/Cas9 to study human diseases (review).","volume":"43","author":"Rodr\u00edguez-Rodr\u00edguez","year":"2019","journal-title":"Int J Mol Med."},{"key":"B54","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-biochem-060815-014607","article-title":"CRISPR\/Cas9 in genome editing and beyond.","volume":"85","author":"Wang","year":"2016","journal-title":"Annu Rev Biochem."},{"key":"B55","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","article-title":"CRISPR\u2013Cas9 structures and mechanisms.","volume":"46","author":"Jiang","year":"2017","journal-title":"Annu Rev Biophys."},{"key":"B56","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41573-020-0084-6","article-title":"Base editing: advances and therapeutic opportunities.","volume":"19","author":"Porto","year":"2020","journal-title":"Nat Rev Drug Discov."},{"key":"B57","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA.","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01197-9","article-title":"CRISPR-Cas9 gene therapy for duchenne muscular dystrophy.","author":"Happi Mbakam","year":"2022","journal-title":"Neurotherapeutics [Internet]."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2015.58","article-title":"Efficient restoration of the dystrophin gene reading frame and protein structure in DMD myoblasts using the CinDel method.","volume":"5","author":"Iyombe-Engembe","year":"2016","journal-title":"Mol Ther Nucleic Acids."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1016\/j.ymthe.2018.08.010","article-title":"CRISPR-induced deletion with sacas9 restores dystrophin expression in dystrophic models in vitro and in vivo.","volume":"26","author":"Duch\u00eane","year":"2018","journal-title":"Mol Ther."},{"key":"B61","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/mt.2015.192","article-title":"CRISPR-mediated genome editing restores dystrophin expression and function in mdx mice.","volume":"24","author":"Xu","year":"2016","journal-title":"Mol Ther."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.ymthe.2018.03.018","article-title":"Functional rescue of dystrophin deficiency in mice caused by frameshift mutations using campylobacter jejuni Cas9.","volume":"26","author":"Koo","year":"2018","journal-title":"Mol Ther."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aav4324","article-title":"CRISPR-Cas9 corrects duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells.","volume":"5","author":"Min","year":"2019","journal-title":"Sci Adv."},{"key":"B64","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.stemcr.2021.12.003","article-title":"CRISPR\/Cas9 editing of directly reprogrammed myogenic progenitors restores dystrophin expression in a mouse model of muscular dystrophy.","volume":"17","author":"Domenig","year":"2022","journal-title":"Stem Cell Rep."},{"key":"B65","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","article-title":"Base editing: precision chemistry on the genome and transcriptome of living cells.","volume":"19","author":"Rees","year":"2018","journal-title":"Nat Rev Genet."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23996-y","article-title":"Efficient precise in vivo base editing in adult dystrophic mice.","volume":"12","author":"Xu","year":"2021","journal-title":"Nat Commun."},{"key":"B67","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1126\/science.aav9973","article-title":"Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos.","volume":"364","author":"Zuo","year":"2019","journal-title":"Science."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abg4910","article-title":"Precise correction of duchenne muscular dystrophy exon deletion mutations by base and prime editing.","volume":"7","author":"Chemello","year":"2021","journal-title":"Sci Adv."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22295-w","article-title":"Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice.","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun."},{"key":"B70","doi-asserted-by":"publisher","first-page":"5635.e","DOI":"10.1016\/j.cell.2021.09.018","article-title":"Enhanced prime editing systems by manipulating cellular determinants of editing outcomes.","volume":"184","author":"Chen","year":"2021","journal-title":"Cell."},{"key":"B71","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/crispr.2021.0085","article-title":"Insertion of the icelandic mutation (A673T) by prime editing: a potential preventive treatment for familial and sporadic alzheimer\u2019s disease.","volume":"5","author":"Tremblay","year":"2022","journal-title":"CRISPR J."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.31.230565","article-title":"Specific mutations in genes responsible for Alzheimer and for duchenne muscular dystrophy introduced by base editing and PRIME editing.","author":"Rousseau","year":"2020","journal-title":"bioRxiv."},{"key":"B73","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2217\/epi.14.36","article-title":"Histone deacetylase inhibitors: a potential epigenetic treatment for c muscular dystrophy.","volume":"6","author":"Consalvi","year":"2014","journal-title":"Epigenomics."},{"key":"B74","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1152\/physrev.00043.2011","article-title":"Satellite cells and the muscle stem cell niche.","volume":"93","author":"Yin","year":"2013","journal-title":"Physiol Rev."},{"key":"B75","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.1111\/febs.12370","article-title":"Tissue-resident mesenchymal stem\/progenitor cells in skeletal muscle: collaborators or saboteurs?","volume":"280","author":"Judson","year":"2013","journal-title":"FEBS J."},{"key":"B76","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/ncb1542","article-title":"Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells.","volume":"9","author":"Dellavalle","year":"2007","journal-title":"Nat Cell Biology."},{"key":"B77","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1083\/jcb.200202092","article-title":"Myogenic specification of side population cells in skeletal muscle.","volume":"159","author":"Asakura","year":"2002","journal-title":"J Cell Biol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/43919","article-title":"Dystrophin expression in the mdx mouse restored by stem cell transplantation.","volume":"401","author":"Gussoni","year":"1999","journal-title":"Nature."},{"key":"B79","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/ncb2025","article-title":"Identification and characterization of a non-satellite cell muscle resident progenitor during postnatal development.","volume":"12","author":"Mitchell","year":"2010","journal-title":"Nat Cell Biology."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/nm1479","article-title":"Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors.","volume":"12","author":"Minetti","year":"2006","journal-title":"Nat Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1002\/art.30238","article-title":"Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis.","volume":"63","author":"Vojinovic","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B82","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","article-title":"Histological effects of givinostat in boys with duchenne muscular dystrophy.","volume":"26","author":"Bettica","year":"2016","journal-title":"Neuromuscul Disord."},{"key":"B83","year":"2021","journal-title":"Italfarmaco Provides Update on Ongoing Clinical Programs with Givinostat in Oral Presentation at XVIII International Conference on Duchenne and Becker Muscular Dystrophy [Internet]."},{"key":"B84","year":"2018","journal-title":"EU\/3\/12\/1009: Orphan Designation for the Treatment of Duchenne Muscular Dystrophy [Internet]."},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1093\/database\/baw153","article-title":"GeneBase 1.1: a tool to summarize data from NCBI gene datasets and its application to an update of human gene statistics.","volume":"2016","author":"Piovesan","year":"2016","journal-title":"Database."},{"key":"B86","doi-asserted-by":"publisher","first-page":"254","DOI":"10.15252\/emmm.201607284","article-title":"Reversible immortalisation enables genetic correction of human muscle progenitors and engineering of next-generation human artificial chromosomes for duchenne muscular dystrophy.","volume":"10","author":"Benedetti","year":"2018","journal-title":"EMBO Mol Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1089\/hum.2019.224","article-title":"Restoration of functional full-length dystrophin after intramuscular transplantation of foamy virus-transduced myoblasts.","volume":"31","author":"Meng","year":"2020","journal-title":"Hum Gene Ther."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV micro-dystrophin gene therapy for duchenne muscular dystrophy.","volume":"26","author":"Duan","year":"2018","journal-title":"Mol Ther."},{"key":"B89","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nm0302-253","article-title":"Modular flexibility of dystrophin: implications for gene therapy of duchenne muscular dystrophy.","volume":"8","author":"Harper","year":"2002","journal-title":"Nat Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"13714","DOI":"10.1073\/pnas.240335297","article-title":"Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model.","volume":"97","author":"Wang","year":"2000","journal-title":"Proc Natl Acad Sci USA."},{"key":"B91","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.omtm.2017.06.006","article-title":"A five-repeat micro-dystrophin gene ameliorated dystrophic phenotype in the severe dba\/2j-mdx model of duchenne muscular dystrophy.","volume":"6","author":"Hakim","year":"2017","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B92","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.amjcard.2015.01.030","article-title":"Dystrophin genotype\u2013cardiac phenotype correlations in duchenne and becker muscular dystrophies using cardiac magnetic resonance imaging.","volume":"115","author":"Tandon","year":"2015","journal-title":"Am J Cardiol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/hmg\/ddab133","article-title":"Proteomic analysis identifies key differences in the cardiac interactomes of dystrophin and micro-dystrophin.","volume":"30","author":"Wang","year":"2021","journal-title":"Hum Mol Genet."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41434-022-00317-6","article-title":"Evaluation of the dystrophin carboxy-terminal domain for micro-dystrophin gene therapy in cardiac and skeletal muscles in the DMDmdx rat model.","volume":"1","author":"Bourdon","year":"2022","journal-title":"Gene Ther."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with duchenne muscular dystrophy: a nonrandomized controlled trial.","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.31851","article-title":"Assessment of rAAVrh.74.MHCK7.micro-dystrophin gene therapy using magnetic resonance imaging in children with duchenne muscular dystrophy.","volume":"4","author":"Willcocks","year":"2021","journal-title":"JAMA Netw Open."},{"key":"B97","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.coviro.2016.08.003","article-title":"In vivo tissue-tropism of adeno-associated viral vectors.","volume":"21","author":"Srivastava","year":"2016","journal-title":"Curr Opin Virol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/hum.2022.29198.bfs","article-title":"After patient death, FDA places hold on pfizer duchenne muscular dystrophy gene therapy trial.","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum Gene Ther."},{"key":"B99","year":"2019","journal-title":"Pfizer Presents Initial Clinical Data on Phase 1b Gene Therapy Study for Duchenne Muscular Dystrophy (DMD) | Pfizer [Internet]."},{"key":"B100","year":"2021","journal-title":"Solid Biosciences Reports 1.5-Year Data from Patients in the Ongoing IGNITE DMD Phase I\/II Clinical Trial of SGT-001 [Internet]."},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2019.113086","article-title":"Stem cell-based therapies for duchenne muscular dystrophy.","volume":"323","author":"Sun","year":"2020","journal-title":"Exp Neurol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10974-019-09550-w","article-title":"Skeletal muscle cell transplantation: models and methods.","volume":"41","author":"Mueller","year":"2020","journal-title":"J Muscle Res Cell Motil."},{"key":"B103","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/mt.2011.193","article-title":"Slowing down differentiation of engrafted human myoblasts into immunodeficient mice correlates with increased proliferation and migration.","volume":"20","author":"Riederer","year":"2012","journal-title":"Mol Ther."},{"key":"B104","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3727\/096368914X685032","article-title":"First study of intra-arterial delivery of myogenic mononuclear cells to skeletal muscles in primates.","author":"Skuk","year":"2014","journal-title":"Cell Transplant."},{"key":"B105","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.nmd.2006.10.003","article-title":"First test of a \u201chigh-density injection\u201d protocol for myogenic cell transplantation throughout large volumes of muscles in a duchenne muscular dystrophy patient: eighteen months follow-up.","volume":"17","author":"Skuk","year":"2007","journal-title":"Neuromuscul Disord."},{"key":"B106","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.omtm.2017.05.002","article-title":"Cell therapy in myology: dynamics of muscle precursor cell death after intramuscular administration in non-human primates.","volume":"5","author":"Skuk","year":"2017","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/964010","article-title":"Stem cell transplantation for muscular dystrophy: the challenge of immune response.","volume":"2014","author":"Maffioletti","year":"2014","journal-title":"Biomed Res Int."},{"key":"B108","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/01.jnen.0000218443.45782.81","article-title":"Dystrophin expression in muscles of duchenne muscular dystrophy patients after high-density injections of normal myogenic cells.","volume":"65","author":"Skuk","year":"2006","journal-title":"J Neuropathol Exp Neurol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.ymthe.2003.11.023","article-title":"Dystrophin expression in myofibers of duchenne muscular dystrophy patients following intramuscular injections of normal myogenic cells.","volume":"9","author":"Skuk","year":"2004","journal-title":"Mol Ther."},{"key":"B110","first-page":"141","article-title":"Human umbilical cord mesenchymal stem cells in the treatment of duchenne muscular dystrophy: safety and feasibility study in india.","volume":"10","author":"Rajput","year":"2015","journal-title":"J Stem Cells."},{"key":"B111","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1750-3639.1996.tb00781.x","article-title":"Utrophin: a structural and functional comparison to dystrophin.","volume":"6","author":"Blake","year":"1996","journal-title":"Brain Pathol."},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000774","article-title":"Utrophin up-regulation by an artificial transcription factor in transgenic mice.","volume":"2","author":"Mattei","year":"2007","journal-title":"PLoS One."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.bbadis.2018.01.030","article-title":"Utrophin up-regulation by artificial transcription factors induces muscle rescue and impacts the neuromuscular junction in mdx mice.","volume":"1864","author":"Pisani","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis."},{"key":"B114","article-title":"High-throughput identification of post-transcriptional utrophin up-regulators for duchenne muscle dystrophy (DMD) therapy.","volume":"10","author":"Loro","year":"2020","journal-title":"Sci Rep."},{"key":"B115","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.omtn.2020.08.031","article-title":"Genome editing-mediated utrophin upregulation in duchenne muscular dystrophy stem cells.","volume":"22","author":"Sengupta","year":"2020","journal-title":"Mol Ther Nucleic Acids."},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15971-w","article-title":"Identification of therapeutics that target eEF1A2 and upregulate utrophin a translation in dystrophic muscles.","volume":"11","author":"P\u00e9ladeau","year":"2020","journal-title":"Nat Commun."},{"key":"B117","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/cpdd.642","article-title":"a phase 1b trial to assess the pharmacokinetics of ezutromid in pediatric duchenne muscular dystrophy patients on a balanced diet.","volume":"8","author":"Muntoni","year":"2019","journal-title":"Clin Pharmacol Drug Dev."},{"key":"B118","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2017.06.443","article-title":"PhaseOut DMD: a phase 2, proof of concept, clinical study of utrophin modulation with ezutromid.","volume":"27","author":"Muntoni","year":"2017","journal-title":"Neuromuscul Disord."},{"key":"B119","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.taap.2004.04.017","article-title":"Toxicology of antisense therapeutics.","volume":"201","author":"Jason","year":"2004","journal-title":"Toxicol Appl Pharmacol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"S325","DOI":"10.3233\/JND-210706","article-title":"The effect of immunomodulatory treatments on anti-dystrophin immune response after aav gene therapy in dystrophin deficient mdx mice.","volume":"8","author":"Li","year":"2021","journal-title":"J Neuromuscul Dis."},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16105","article-title":"Long-term microdystrophin gene therapy is effective in a canine model of duchenne muscular dystrophy.","volume":"8","author":"Le Guiner","year":"2017","journal-title":"Nat Commun."},{"key":"B122","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/mt.2013.244","article-title":"Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery.","volume":"22","author":"Chicoine","year":"2014","journal-title":"Mol Ther."},{"key":"B123","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.omtm.2017.01.003","article-title":"Effective depletion of pre-existing anti-aav antibodies requires broad immune targeting.","volume":"4","author":"Velazquez","year":"2017","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","article-title":"Dystrophin immunity in duchenne\u2019s muscular dystrophy.","volume":"363","author":"Mendell","year":"2010","journal-title":"N Engl J Med."},{"key":"B125","year":"2021","journal-title":"Cellular, Tissue, and Gene Therapies Advisory Committee September 2-3, 2021 Meeting Announcement - 09\/02\/2021 - 09\/03\/2021 [Internet]."},{"key":"B126","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1089\/hum.2020.29133.bfs","article-title":"After third death, audentes\u2019 AT132 remains on clinical hold.","volume":"31","author":"Philippidis","year":"2020","journal-title":"Hum Gene Ther."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1089\/hum.2021.29182.bfs","article-title":"Fourth boy dies in clinical trial of astellas\u2019 AT132.","volume":"32","author":"Philippidis","year":"2021","journal-title":"Hum Gene Ther."},{"key":"B128","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1016\/j.ymthe.2021.08.031","article-title":"AAV integration in human hepatocytes.","volume":"29","author":"Dalwadi","year":"2021","journal-title":"Mol Ther."},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3390\/v11010028","article-title":"Viral delivery systems for CRISPR.","volume":"11","author":"Xu","year":"2019","journal-title":"Viruses."},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1063\/1.5087122","article-title":"Challenges and opportunities in exosome research\u2014Perspectives from biology, engineering, and cancer therapy.","volume":"3","author":"Li","year":"2019","journal-title":"APL Bioeng."},{"key":"B131","doi-asserted-by":"publisher","first-page":"GE01","DOI":"10.7860\/JCDR\/2015\/10443.5394","article-title":"Non viral vectors in gene therapy- an overview.","volume":"9","author":"Ramamoorth","year":"2015","journal-title":"J Clin Diagn Res."},{"key":"B132","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","article-title":"Adeno-associated virus serotypes: vector toolkit for human gene therapy.","volume":"14","author":"Wu","year":"2006","journal-title":"Mol Ther."},{"key":"B133","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1089\/hum.2013.164","article-title":"Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice.","volume":"25","author":"Koo","year":"2014","journal-title":"Hum Gene Ther."},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.heares.2019.107857","article-title":"Dual-AAV delivery of large gene sequences to the inner ear.","volume":"394","author":"Reisinger","year":"2020","journal-title":"Hear Res."},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav4523","article-title":"Intein-mediated protein trans-splicing expands adeno-associated virus transfer capacity in the retina.","volume":"11","author":"Tornabene","year":"2019","journal-title":"Sci Transl Med."},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.25.432823","article-title":"Efficient in vivo genome editing mediated by stem cells-derived extracellular vesicles carrying designer nucleases.","author":"Bobis-Wozowicz","year":"2021","journal-title":"bioRxiv."},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14957-y","article-title":"Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping.","volume":"11","author":"Gee","year":"2020","journal-title":"Nat Commun."},{"key":"B138","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000323","article-title":"Antisense oligonucleotides.","volume":"5","author":"Scoles","year":"2019","journal-title":"Neurol Genet."},{"key":"B139","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1128\/jvi.77.6.3495-3504.2003","article-title":"Genetic fate of recombinant adeno-associated virus vector genomes in muscle.","volume":"77","author":"Schnepp","year":"2003","journal-title":"J Virol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1128\/JVI.75.15.6969-6976.2001","article-title":"Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo.","volume":"75","author":"Nakai","year":"2001","journal-title":"J Virol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1089\/hum.2017.025","article-title":"\/MAR element facilitates episomal long-term persistence of adeno-associated virus vector genomes in proliferating cells.","volume":"28","author":"Hagedorn","year":"2017","journal-title":"Hum Gene Ther."},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228707","article-title":"Hybrid adeno-associated viral vectors utilizing transposase-mediated somatic integration for stable transgene expression in human cells.","volume":"15","author":"Zhang","year":"2020","journal-title":"PLoS One."},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.146511","article-title":"Micro-dystrophin gene therapy prevents heart failure in an improved Duchenne muscular dystrophy cardiomyopathy mouse model.","volume":"6","author":"Howard","year":"2021","journal-title":"JCI Insight."},{"key":"B144","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1126\/science.aba8853","article-title":"Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants.","volume":"368","author":"Walton","year":"2020","journal-title":"Science."},{"key":"B145","first-page":"1","article-title":"Engineered pegRNAs improve prime editing efficiency.","volume":"4","author":"Nelson","year":"2021","journal-title":"Nat Biotechnol."},{"key":"B146","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy.","volume":"21","author":"Li","year":"2020","journal-title":"Nat Rev Genet."},{"key":"B147","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/med\/9780199681488.003.0001","article-title":"Duchenne muscular dystrophy.","volume":"7","author":"Duan","year":"2021","journal-title":"Nat Rev Dis Primers."},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004840117","article-title":"Toward the correction of muscular dystrophy by gene editing.","volume":"118","author":"Olson","year":"2021","journal-title":"Proc Natl Acad Sci USA."},{"key":"B149","first-page":"3148","article-title":"[Introduction of rod-deleted dystrophin cDNA, delta DysM3, into mdx skeletal muscle using adenovirus vector].","volume":"55","author":"Yuasa","year":"1997","journal-title":"Nihon Rinsho."},{"key":"B150","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1101\/gad.234468.113","article-title":"HDAC-regulated myomiRs control BAF60 variant exchange and direct the functional phenotype of fibro-adipogenic progenitors in dystrophic muscles.","volume":"28","author":"Saccone","year":"2014","journal-title":"Genes Dev."},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002342","article-title":"Stem cell\u2013mediated transfer of a human artificial chromosome ameliorates muscular dystrophy.","volume":"3","author":"Tedesco","year":"2011","journal-title":"Sci Transl Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.859930\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T23:07:42Z","timestamp":1648595262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.859930\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,28]]},"references-count":151,"alternative-id":["10.3389\/fmed.2022.859930"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.859930","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,28]]},"article-number":"859930"}}